Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Methods of using immunoglobulin (Ig) compositions

a technology of immunoglobulin and composition, applied in the field of immunoglobulin composition, can solve problems such as white blood cells becoming trapped

Inactive Publication Date: 2004-12-02
CENT BIOMEDIA
View PDF8 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0014] Of particular import, the inventor has discovered a novel method of enhancing weight gain in patients, particularly cattle and other livestock, wherein the method comprises administering one or more doses of an immunoglobulin composition to the animal. In this method, the Ig composition may be administered in any conventional manner or is preferably administered via a novel method of subcutaneous injection which is particularly convenient and effective for this purpose.
[0018] In another embodiment of the invention, the inventor has developed an improved Ig composition and method of making the same whereby the composition is prepared from whole blood without permitting the blood to clot before extraction. It is believed that this improved method increases the overall amount of immunoglobulins, complement, transfer factors and other immune constituents extracted from the whole blood. The improved method includes the steps of collecting whole blood from one or more donors, wherein the donors have known immunity for a variety of ailments. An anti-coagulant such as citrate-phosphate-dextrose (CPD) is then mixed with the collected blood in sufficient amount to prevent the blood from clotting. The anti-coagulant and whole blood mixture is then allowed to stand undisturbed until the red blood cells contained within the blood settle to the bottom of the collection vessel forming a bottom red blood cell layer. The white blood cells and liquid plasma form middle and upper layers respectively. In some species, it may be necessary to subject the anti-coagulant and whole blood mixture to centrifugation in order to obtain this layered separation.

Problems solved by technology

Furthermore, it is believed that white blood cells may become trapped within the red blood cells during the clotting process such that a portion of these cells remain intact and do not expel transfer factors into the serum.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0022] Part A--Novel Methods of Using Immunoglobulin Compositions

[0023] In several embodiments of the invention, novel methods of using and administering immunoglobulin (Ig) compositions are disclosed. For purposes of each of these inventive methods, any Ig composition as hereafter defined meeting known standards of sterility and recipient compatibility shall be considered suitable. The term "Ig composition" shall mean any composition comprising a concentrated amount of one or more immunoglobulins selected from the group of alpha, beta and gamma globulins and / or comprising other antibodies identified as providing an immune response. The Ig composition preferably comprises a concentrated amount of one or more gamma globulins selected from the group consisting of IgG, IgG.sub.T, IgM, IgA, IgE and / or IgD, and most preferably includes IgG immunoglobulins specific to a variety of different antigens.

[0024] The concentration level of the composition can be assessed with reference to the Ig...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
timeaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

The invention is directed to methods of using Ig compositions to prevent and / or treat humans, livestock and / or domesticated animals suffering from a variety of disorders. The Ig composition comprises a concentrated amount of one or more immunoglobulins selected from the group consisting of alpha, beta, and gamma globulins. Preferably, the Ig composition comprises other antibodies identified as providing an immune response and / or immune factors such as complement. The Ig composition preferably includes immunoglobulins specific to a variety of antigens.

Description

[0001] This application is a Continuation of U.S. patent application Ser. No. 09 / 586,510, filed Jun. 2, 2002, which is a Continuation of U.S. patent application Ser. No. 08 / 685,052, filed Jul. 23, 1996, now abandoned, which is a Continuation-in-Part of U.S. patent application Ser. No. 08 / 349,010, filed Dec. 2, 1994, which is now issued as U.S. Pat. No. 5,548,066, all of which are hereby incorporated herein by reference.[0002] Not applicable.[0003] 1. Field of the Invention[0004] The present invention is generally directed to immunoglobulin (Ig) compositions and methods of therapeutically using Ig compositions in animals including humans, livestock and domesticated animals. Several embodiments of the invention are directed to unique and novel methods of using Ig compositions in the treatment of certain maladies or conditions. These methods include the use of an Ig composition for treating stress induced respiratory disorders, diarrhea such as diarrhea caused by Parvovirus in canines,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K14/52C07K16/06G21K5/00
CPCC07K14/52C07K16/06G21K5/00Y10S530/829Y10S530/83Y10S530/831
Inventor SKELLY, WILLIAM G.
Owner CENT BIOMEDIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products